Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)

Sherise D. Ferguson; Elena I. Fomchenko; Renato A. Guerrieri; Isabella C. Glitza Oliva

doi:10.3389/fonc.2021.800053

Frontiers in Oncology (Jan 2022)

Challenges and Advances in Diagnosis and Treatment of Leptomeningeal Disease (LMD)

Sherise D. Ferguson,
Elena I. Fomchenko,
Renato A. Guerrieri,
Isabella C. Glitza Oliva

Affiliations

Sherise D. Ferguson: Department of Neurosurgery, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
Elena I. Fomchenko: Department of Neurosurgery, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
Renato A. Guerrieri: Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, United States
Isabella C. Glitza Oliva: Department of Melanoma Medical Oncology, University of Texas, MD Anderson Cancer Center, Houston, TX, United States

DOI: https://doi.org/10.3389/fonc.2021.800053
Journal volume & issue: Vol. 11

Abstract

Read online

Leptomeningeal disease (LMD) is a devastating category of CNS metastasis with a very poor prognosis and limited treatment options. With maximal aggressive therapy, survival times remain short and, without treatment, prognosis is measured in weeks. Both LMD diagnosis and treatment are challenging topics within neuro-oncology. In this review, we discuss the advances in LMD diagnosis with a focus on the role of circulating tumor DNA (ctDNA) and discuss the role of targeted and immunotherapy in LMD treatment.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords